Skip to main content
Livermore
Livermore
ZHEN

Cytek Biosciences, Inc.

CTKB
Exchange
Nasdaq
Industry
Laboratory Analytical Instruments
SEC CIK
0001831915

No open-market purchases or sales by Cytek Biosciences, Inc. insiders were filed in the last 90 days; 154 institutions reported holding it in 13F filings for Q2 2026, worth $361.0M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.

Holders of 5% or more of CTKB

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Cytek Biosciences, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of CTKB
HolderLatest formStakeChangeFirst filedLatest filingFiling
BlackRock, Inc.13G/A14.30%18.5M shares–Feb 5, 20251 filingFeb 5, 2025SEC
Vanguard Group Inc13G/A7.51%9.62M shares–Apr 30, 20251 filingApr 30, 2025SEC
Brown Capital Management LLC13G/A5.89%7.46M shares–May 15, 20251 filingMay 15, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

4 Schedule 13D and 13G filings on Cytek Biosciences, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on CTKB
Filed (ET)FilerFormStakeChangeEvent dateFiling
May 15, 20252:07 PM ETBrown Capital Management LLC13G/A5.89%7.46M shares–Mar 31, 2025SEC
Apr 30, 202510:57 AM ETVanguard Group Inc13G/A7.51%9.62M shares–Mar 31, 2025SEC
Feb 14, 20256:29 PM ETRa Capital Management, L.P.and 3 others13G/A0.00%0 shares–Below 5%Dec 31, 2024SEC
Feb 5, 20251:23 PM ETBlackRock, Inc.13G/A14.30%18.5M shares–Dec 31, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Cytek Biosciences, Inc. shares.

No Form 144 notices for Cytek Biosciences, Inc. are on file.